Wajahat Z Mehal

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/1668056/publications.pdf

Version: 2024-02-01

78 papers

8,764 citations

36 h-index 69250 77 g-index

80 all docs 80 docs citations

80 times ranked

13835 citing authors

#	Article	IF	CITATIONS
1	Inflammasome-mediated dysbiosis regulates progression of NAFLD and obesity. Nature, 2012, 482, 179-185.	27.8	2,026
2	Caspases 3 and 7: Key Mediators of Mitochondrial Events of Apoptosis. Science, 2006, 311, 847-851.	12.6	1,003
3	Sterile Inflammation in the Liver. Gastroenterology, 2012, 143, 1158-1172.	1.3	553
4	Acetaminophen-induced hepatotoxicity in mice is dependent on Tlr9 and the Nalp3 inflammasome. Journal of Clinical Investigation, 2009, 119, 305-14.	8.2	493
5	Phosphatidylserine Receptor Is Required for Clearance of Apoptotic Cells. Science, 2003, 302, 1560-1563.	12.6	368
6	Intestinal fungi contribute to development of alcoholic liver disease. Journal of Clinical Investigation, 2017, 127, 2829-2841.	8.2	336
7	TLR9 and the NLRP3 Inflammasome Link Acinar Cell Death With Inflammation in Acute Pancreatitis. Gastroenterology, 2011, 141, 358-369.	1.3	241
8	Systemic inflammatory response and serum lipopolysaccharide levels predict multiple organ failure and death in alcoholic hepatitis. Hepatology, 2015, 62, 762-772.	7.3	230
9	Apoptotic hepatocyte DNA inhibits hepatic stellate cell chemotaxis via toll-like receptor 9. Hepatology, 2007, 46, 1509-1518.	7. 3	220
10	Glucocerebrosidase gene-deficient mouse recapitulates Gaucher disease displaying cellular and molecular dysregulation beyond the macrophage. Proceedings of the National Academy of Sciences of the United States of America, 2010, 107, 19473-19478.	7.1	198
11	Bile acids initiate cholestatic liver injury by triggering a hepatocyte-specific inflammatory response. JCI Insight, 2017, 2, e90780.	5.0	181
12	Scraping fibrosis: Expressway to the core of fibrosis. Nature Medicine, 2011, 17, 552-553.	30.7	180
13	A prognostic rule for elderly patients admitted with community-acquired pneumonia. American Journal of Medicine, 1999, 106, 20-28.	1.5	155
14	Dysregulation of serum bile acids and FGF19 in alcoholic hepatitis. Journal of Hepatology, 2018, 69, 396-405.	3.7	144
15	Extracellular Mitochondrial DNA Is Generated by Fibroblasts and Predicts Death in Idiopathic Pulmonary Fibrosis. American Journal of Respiratory and Critical Care Medicine, 2017, 196, 1571-1581.	5.6	140
16	The Gordian Knot of dysbiosis, obesity and NAFLD. Nature Reviews Gastroenterology and Hepatology, 2013, 10, 637-644.	17.8	134
17	P2X7 receptor-mediated purinergic signaling promotes liver injury in acetaminophen hepatotoxicity in mice. American Journal of Physiology - Renal Physiology, 2012, 302, G1171-G1179.	3.4	133
18	Adenosine Deamination Sustains Dendritic Cell Activation in Inflammation. Journal of Immunology, 2007, 179, 1884-1892.	0.8	121

#	Article	IF	CITATIONS
19	Sterile Inflammatory Response in Acute Pancreatitis. Pancreas, 2012, 41, 353-357.	1.1	118
20	Modulation of Cell Adhesion and Motility in the Immune System by Myo1f. Science, 2006, 314, 136-139.	12.6	102
21	Critical role for the \hat{A} regulatory subunits of Cav channels in T lymphocyte function. Proceedings of the National Academy of Sciences of the United States of America, 2006, 103, 15529-15534.	7.1	101
22	Immunological mechanisms and therapeutic targets of fatty liver diseases. Cellular and Molecular Immunology, 2021, 18, 73-91.	10.5	98
23	Inflammasome components Asc and caspase-1 mediate biomaterial-induced inflammation and foreign body response. Proceedings of the National Academy of Sciences of the United States of America, 2011, 108, 20095-20100.	7.1	91
24	Antigen Presentation by Liver Cells Controls Intrahepatic T Cell Trapping, Whereas Bone Marrow-Derived Cells Preferentially Promote Intrahepatic T Cell Apoptosis. Journal of Immunology, 2001, 167, 667-673.	0.8	83
25	Adenosine induces loss of actin stress fibers and inhibits contraction in hepatic stellate cells via Rho inhibition. Hepatology, 2009, 49, 185-194.	7.3	82
26	Ursodeoxycholic acid diminishes Fas-ligand-induced apoptosis in mouse hepatocytes. Hepatology, 2002, 36, 49-54.	7.3	78
27	Adenosine inhibits cytosolic calcium signals and chemotaxis in hepatic stellate cells. American Journal of Physiology - Renal Physiology, 2007, 292, G395-G401.	3.4	71
28	Gaucher disease gene <i>GBA</i> functions in immune regulation. Proceedings of the National Academy of Sciences of the United States of America, 2012, 109, 10018-10023.	7.1	70
29	Comparison of imatinib, nilotinib and silymarin in the treatment of carbon tetrachloride-induced hepatic oxidative stress, injury and fibrosis. Toxicology and Applied Pharmacology, 2011, 252, 165-175.	2.8	66
30	Cell Death and Fibrogenesis. Seminars in Liver Disease, 2010, 30, 226-231.	3.6	62
31	Inflammasome biology in fibrogenesis. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 2013, 1832, 979-988.	3.8	54
32	Nilotinib induces apoptosis and autophagic cell death of activated hepatic stellate cells via inhibition of histone deacetylases. Biochimica Et Biophysica Acta - Molecular Cell Research, 2013, 1833, 1992-2003.	4.1	49
33	î²-Hydroxybutyrate protects from alcohol-induced liver injury via a Hcar2-cAMP dependent pathway. Journal of Hepatology, 2018, 69, 687-696.	3.7	48
34	Inflammasomes in pancreatic physiology and disease. American Journal of Physiology - Renal Physiology, 2015, 308, G643-G651.	3.4	47
35	Kupffer cells required for high affinity peptide-induced deletion, not retention, of activated CD8+ T cells by mouse liver. Hepatology, 2004, 39, 1017-1027.	7.3	44
36	In Vitro and In Vivo Protection of Stellate Cells from Apoptosis by Leptin. Digestive Diseases and Sciences, 2006, 51, 1697-1705.	2.3	36

#	Article	IF	CITATIONS
37	Targeting Cell Death and Sterile Inflammation Loop for the Treatment of Nonalcoholic Steatohepatitis. Seminars in Liver Disease, 2016, 36, 027-036.	3.6	35
38	Therapeutic strategies in inflammasome mediated diseases of the liver. Journal of Hepatology, 2013, 58, 1047-1052.	3.7	31
39	Activation of adenosine receptor A2A increases HSC proliferation and inhibits death and senescence by down-regulation of p53 and Rb. Frontiers in Pharmacology, 2014, 5, 69.	3.5	31
40	HCV Response in Patients With End Stage Renal Disease Treated With Combination Pegylated Interferon \hat{l}_{\pm} -2a and Ribavirin. Journal of Clinical Gastroenterology, 2009, 43, 477-481.	2.2	29
41	Therapeutic Opportunities in Damage-Associated Molecular Pattern-Driven Metabolic Diseases. Antioxidants and Redox Signaling, 2015, 23, 1305-1315.	5.4	28
42	Sterile inflammation in the liver and pancreas. Journal of Gastroenterology and Hepatology (Australia), 2013, 28, 61-67.	2.8	27
43	A Novel Small-Molecule Enantiomeric Analogue of Traditional (â^')-Morphinans Has Specific TLR9 Antagonist Properties and Reduces Sterile Inflammation-Induced Organ Damage. Journal of Immunology, 2013, 190, 4297-4304.	0.8	27
44	Efficacy of individualised diets in patients with irritable bowel syndrome: a randomised controlled trial. BMJ Open Gastroenterology, 2017, 4, e000164.	2.7	27
45	The gut-liver axis: A busy two-way street. Hepatology, 2012, 55, 1647-1649.	7.3	24
46	Requirement of Voltage-Gated Calcium Channel Â4 Subunit for T Lymphocyte Functions. Science, 2005, 307, 117-121.	12.6	22
47	Adenosine inhibits chemotaxis and induces hepatocyte-specific genes in bone marrow mesenchymal stem cells. Hepatology, 2010, 51, NA-NA.	7.3	22
48	The novel TLR9 antagonist COV08-0064 protects from ischemia/reperfusion injury in non-steatotic and steatotic mice livers. Biochemical Pharmacology, 2016, 112, 90-101.	4.4	22
49	Enhanced Oral Tolerance in Transgenic Mice with Hepatocyte Secretion of IL-10. Journal of Immunology, 2005, 175, 3577-3583.	0.8	17
50	$GSK3\hat{I}^2$ mediates the spatiotemporal dynamics of NLRP3 inflammasome activation. Cell Death and Differentiation, 2022, 29, 2060-2069.	11.2	17
51	A distinct nitric oxide and adenosine A1 receptor dependent hepatic artery vasodilatatory response in the CCl4-cirrhotic liver. Liver International, 2010, 30, 988-994.	3.9	16
52	Caspase-12, but Not Caspase-11, Inhibits Obesity and Insulin Resistance. Journal of Immunology, 2016, 196, 437-447.	0.8	16
53	NASH and HCC Are Driven by Different Signaling Pathways with a Common Regulator. Cell Metabolism, 2019, 29, 3-4.	16.2	16
54	Involvement of CD1 in Peripheral Deletion of T Lymphocytes Is Independent of NK T Cells. Journal of Immunology, 2001, 166, 3090-3097.	0.8	15

#	Article	IF	CITATIONS
55	TGF- \hat{l}^2 signaling regulates CD8+ T cell responses to high- and low-affinity TCR interactions. International Immunology, 2005, 17, 531-538.	4.0	15
56	HIF- \hat{l} ± is a major and complex player in alcohol induced liver diseases. Journal of Hepatology, 2012, 56, 311-312.	3.7	15
57	Adenine Induces Differentiation of Rat Hepatic Stellate Cells. Digestive Diseases and Sciences, 2012, 57, 2371-2378.	2.3	11
58	Incorporating Weight Loss Medications Into Hepatology Practice for Nonalcoholic Steatohepatitis. Hepatology, 2019, 70, 1443-1456.	7.3	11
59	Colchicine-associated Ring Mitosis in Liver Biopsy and Their Clinical Implications. Journal of Clinical Gastroenterology, 2008, 42, 1060-1062.	2.2	9
60	Intrahepatic T cell survival versus death: which one prevails and why?. Journal of Hepatology, 2003, 39, 1070-1071.	3.7	8
61	Role of sterile inflammation in fatty liver diseases. Liver Research, 2018, 2, 21-29.	1.4	8
62	New approaches for fibrosis regression in alcoholic cirrhosis. Hepatology International, 2016, 10, 773-778.	4.2	6
63	A leukocyte activation test identifies food items which induce release of DNA by innate immune peripheral blood leucocytes. Nutrition and Metabolism, 2018, 15, 26.	3.0	4
64	The Intestinal Microbiome, Plasma Metabolome, and Liver Transcriptome: A Conspiracy Driving Hepatic Steatosis. Hepatology, 2019, 70, 741-744.	7.3	4
65	Blocking intrahepatic deletion of activated CD8+ T cells by an altered peptide ligand. Cellular Immunology, 2005, 238, 31-37.	3.0	3
66	Drug development of nonalcoholic fatty liver disease: challenges in research, regulatory pathways, and study endpoints. Expert Opinion on Drug Discovery, 2021, 16, 125-134.	5.0	3
67	Constitutive NLRP3 activation: Too much of a bad thing. Hepatology, 2014, 59, 761-763.	7.3	2
68	DNA: Adding injury to insult. Hepatology, 2015, 61, 35-36.	7.3	2
69	We are not in kansas anymore: The unfamiliar landscape of NASH. Hepatology, 2016, 63, 682-684.	7.3	2
70	Acetyl-Coenzyme A carboxylase inhibition Delivers, as Anticipated, for Patients With Nonalcoholic Steatohepatitis. Gastroenterology, 2018, 155, 1304-1306.	1.3	2
71	A disease-promoting role of the intestinal mycobiome in non-alcoholic fatty liver disease. Journal of Hepatology, 2022, 76, 765-767.	3.7	2
72	Who is the scientist in bio-medical research, the author or the reviewer?. Frontiers in Pharmacology, 2014, 5, 50.	3.5	1

#	Article	IF	CITATIONS
73	The multi-dimensional role of intestinal HIFs in liver pathobiology. Journal of Hepatology, 2018, 69, 772-773.	3.7	1
74	Medical Approach for Weight Loss in Nonalcoholic Fatty Liver Disease. Current Hepatology Reports, 2019, 18, 444-454.	0.9	1
75	A digital pathology tool for quantification of color features in histologic specimens. Bioengineering and Translational Medicine, 2022, 7, e10242.	7.1	1
76	Food Reactivity on the ALCAT Leukocyte Activation Test Is Associated with Upregulation of CD11b on T Cells. Journal of Alternative and Complementary Medicine, 2014, 20, A35-A36.	2.1	0
77	From mice to humans: Unravelling the genetic levers of NASH. Journal of Hepatology, 2020, 73, 749-751.	3.7	O
78	Nonalcoholic Fatty Liver Disease in the Post Liver Transplant Patient. Current Transplantation Reports, 2020, 7, 332-339.	2.0	0